Background/Aims: Kidney injury molecule-1 (KIM-1) is highly expressed in renal tubular cells after injury and is usually regarded as an early biomarker of acute kidney injury(AKI). The aim of this study was to determine the role of KIM-1 in the development of renal tubular injury. Methods: Clinical samples, three different animal models and in vitro experiments were utilized to determine the possible mechanism underlying the involvement of KIM-1 in kidney injury. Results: in AKI and chronic kidney disease (CKD) patients than in healthy volunteers, and urinary to the results of our research involving three different mouse models, KIM-1 expression was transwell, western blotting and real-time PCR data showed that macrophage migration and phenotype transitions were mediated by KIM-1 through the mitogen-activated protein kinase with respect to these macrophage phenotype changes and migration. Conclusions: KIM-1 expression was markedly elevated in both acute and chronic kidney injury and may play a pivotal role in macrophage activation via the MAPK pathway in kidney disease.
Introduction
Kidney disease is a worldwide public health problem affecting millions of people from all racial and ethnic groups [1] . Loss of renal function during kidney disease may be rapid and reversible, as in the case in acute kidney injury (AKI). However, in chronic kidney disease (CKD), renal function declines slowly, and no prominent symptoms develop during the early stages of the disease. Both AKI and CKD may progress to end-stage renal disease (ESRD), which requires renal replacement therapy. Despite the existence of various interventions that can delay kidney disease progression, the number of patients who reach ESRD has incomplete understanding of the mechanisms underlying the processes of regeneration and healing from kidney disease.
Tubulointerstitial injury is a common kidney disease progression pathway in which renal tubular cells play a crucial role [3] . Notably, kidney tubules possess a remarkable capacity to self-repair and regenerate following injury. Kidney injury molecule-1 (KIM-1), a type-1 transmembrane protein, is an emerging biomarker whose expression and release are induced in renal tubular cells after injury [4, 5] . Previous reports involving rat models have shown that KIM-1 is an outstanding indicator of kidney injury and is a better predictor of kidney injury than serum creatinine [4] . Our previous studies also reported that urinary few studies have focused on the function and mechanism underlying the function of KIM-1 in CKD. Thus, whether KIM-1 is "friend" or "foe'' in kidney injury remains a controversial subject.
Macrophage accumulation within the kidney occurs in most types of primary and secondary human glomerulonephritis [9] . The density of macrophage accumulation correlates tubular atrophy. The results of studies in both immune and non-immune-initiated models of during kidney injury [10] . Targeting macrophages and their functions will lead to improved outcomes in many kidney diseases.
Moreover, in a clinical study of biopsy specimens from 102 cases of various renal that KIM-1 was primarily present in regions with interstitial macrophages. The relationship between KIM-1 expression and macrophages is still unknown. The Bonventre group studies about KIM-1 have hypothesized that KIM-1 may play a key role in the crosstalk between injured tubular cells and macrophages [12, 13] . Accordingly, in this study, we used three animal models, as well as in vitro experiments and clinical samples, to determine the possible role of KIM-1 in kidney injury. We used macrophage cultures to determine the potential effects of KIM-1 on macrophage migration and activation. In addition, we tested the hypothesis that patients with kidney injury have higher blood and urinary KIM-1 concentrations than healthy people and that KIM-1 regulates macrophage migration and activation via the mitogen-activated protein kinase (MAPK) signalling pathway in kidney disease.
Materials and Methods

Selection of Patient Study Groups
Single spot urine samples and corresponding plasma samples were obtained from healthy individuals, patients with AKI, and patients with CKD. Healthy volunteers from the Health Examination Center of Renji diseases, and metabolic disease were enrolled in the study. The study was approved by the Ethics Committee of Renji Hospital. All participating subjects gave written consent to participate in the study, according to the Declaration of Helsinki. Patients with AKI from the Department of Urology and Nephrology, Renji Hospital, 2 for 3 months or longer. CKD urine and plasma samples were collected from outpatients attending a general nephrology clinic at Ren Ji Hospital, Shanghai Jiao Tong University.
Cisplatin-induced AKI model
after cisplatin treatment.
acids (AA) (Sigma, USA) or saline alone. Plasma and tissue samples were collected and analysed on days 3, tissue samples were collected and analysed.
Histologic Evaluation of mouse kidneys from different models
eosin (HE) and Masson trichrome. Tubular damage in these HE-stained kidney sections was examined under a light microscope and scored based on the presence of morphologic changes signifying tubular cell necrosis normal kidney tissue samples from the site opposite a tumour in one nephrectomy patient were used as microscopy was performed with a Nikon microscope (Nikon, Melville, NY, USA).
HK-2 Cell Culture and Treatments
Human kidney tubular epithelial (HK-2) cells were purchased from American Type Culture Collection
Results
Increased plasma and urinary KIM-1 expression was noted in AKI and CKD patients
Thirty healthy volunteers, 30 AKI patients, and 30 CKD patients were recruited for the cross-sectional clinical study. AKI samples were chosen as close in time as possible to peak serum creatinine values. The demographic characteristics and clinical descriptions of the entire study population, as well as its serum creatinine level, eGFR, and urinary and plasma KIM-1 levels, are shown in Table 2 . The results showed that both plasma and urinary volunteers (P<0.01) (Fig. 1 A) . Furthermore, urinary KIM-1 levels were markedly higher in CKD patients than in AKI patients (P<0.01) (Fig. 1,B) . The scatterplot results demonstrated the existence of a negative correlation between plasma KIM-1 levels and the estimated ,C), as well as -0.333, P<0.01) (Fig. 1,D) . However, the eGFR was not correlated with plasma KIM-1 or urinary KIM-1 levels in AKI and CKD patients after subset analysis (Fig. 2) . The western blotting results for protein concentrations in urine also indicated that urinary KIM-1 was overexpressed in both AKI and CKD patients (Fig. 1,E) . These results indicated that both plasma and urinary KIM-1 levels were increased in AKI and CKD patients and may be associated with the degree of renal damage. After exposure to recombinant KIM-1 for 12 hours, the mRNA expression levels of M1 activate macrophages towards the M1 phenotype. However, when the cells were pretreated Discussion KIM-1 is widely recognized as an early biomarker of AKI [5] . Due to its potential utility as a therapeutic target and biomarker for kidney injury, KIM-1 has received increasing attention. Previous studies focused mostly on the diagnostic value of KIM-1, particularly the diagnostic in vitro.
tion (C) using an ELISA kit. Western blotting determined KIM-1 expression levels in the lysates from the groups and the control group. in kidney disease is intricate. KIM-1 can be detected in blood, a phenomenon that has been attributed to the loss of tubular cell polarity, increases in transepithelial permeability, and varied across the different animal models. We used cisplatin to establish a model of acute kidney injury that could be healed. However, the mice that were treated with AA developed were elevated during the early stage of AKI in these two animal models, but the outcomes of the models were completely different. Sustained KIM-1 expression may be associated with in kidney tissues in vivo suggested that sustained KIM-1 expression, not sustained increases that KIM-1 may be involved in the occurrence and progression of kidney injury.
1 is thought to confer a phagocytic phenotype on kidney epithelial cells that contributes to these studies focused mainly on the expression and function of KIM-1 at certain disease stages. Our study observed the changes in KIM-1 expression during different stages of renal injury by performing clinical research and animal experiments. In the current study, we not only observed that KIM-1 expression increased during the early stage of kidney injury but our in vitro study results indicated that KIM-1 expression was related to macrophage migration and was inclined to activate macrophages towards the M1 phenotype and that the MAPK signalling pathway was involved in the effects of KIM-1 on macrophages. Although could promote macrophage migration and phenotype changes, our results could not show a clear link between KIM-1 and macrophage phenotype transformation in vivo ed that KIM-1 seemed to regulate macrophages via the MAPK signalling pathway in kidney disease.
cross-sectional study. On the basis of the results our study of three different mice models, we kidney slides and mouse kidney injury slides, we determined that KIM-1-positive tubules studies have reported that KIM-1 and macrophages exhibit similar localization in kidney injury [11, 19] . Our experiments regarding macrophages further demonstrated that KIM-1 could promote macrophage migration and phenotype changes. 
